Laura Tosi

This early-phase trial is testing whether burosumab, a drug already approved for X-linked hypophosphatemia (XLH), can safely raise phosphate levels in a single patient with cutaneous skeletal hypophosphatemia syndrome (CSHS). Both conditions involve abnormally high FGF23 activity…